 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | shRNA-modified CD34+ cell therapy / Kanglin Biotech
Trial completion date, Trial primary completion date: An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients. (clinicaltrials.gov) - Feb 19, 2020
P1, N=6, Recruiting, Sponsor: Shanghai Public Health Clinical Center
Trial completion date: Jan 2020 --> Dec 2020 | Trial primary completion date: Jul 2018 --> Dec 2020
- | shRNA-modified CD34+ cell therapy / Kanglin Biotech
New P1 trial: An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients. (clinicaltrials.gov) - May 8, 2018
P1, N=6, Recruiting, Sponsor: Shanghai Public Health Clinical Center